Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

Phase 1/2 Unknown 22 enrolled University of Sao Paulo Fundação de Amparo à Pesquisa do Estado de São Paulo · collab Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP (FAEPA) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic retinopathy.

Timeline

Start: 2008-09
Primary completion: 2010-03
Completion: 2010-03

Publications

Messias A, Ramos Filho JA, Messias K, Almeida FP, Costa RA, Scott IU, Gekeler F, Jorge R. Electroretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Doc Ophthalmol. 2012 Jun;124(3):225-36. doi: 10.1007/s10633-012-9322-5. Epub 2012 Mar 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Intravitreal

Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

Summary

Timeline

Publications

Drugs

Indications